Freeline Therapeutics Holdings plc Quarterly Depreciation, Depletion and Amortization in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
Freeline Therapeutics Holdings plc quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q1 2020 to Q1 2023.
  • Freeline Therapeutics Holdings plc Depreciation, Depletion and Amortization for the quarter ending March 31, 2023 was $320K, a 40.9% decline year-over-year.
  • Freeline Therapeutics Holdings plc annual Depreciation, Depletion and Amortization for 2022 was $1.74M, a 27.2% decline from 2021.
  • Freeline Therapeutics Holdings plc annual Depreciation, Depletion and Amortization for 2021 was $2.39M, a 24.9% increase from 2020.
  • Freeline Therapeutics Holdings plc annual Depreciation, Depletion and Amortization for 2020 was $1.91M, a 24.2% increase from 2019.
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $320K -$221K -40.9% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q1 2022 $541K -$32K -5.59% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 $573K +$78K +15.8% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-10
Q1 2020 $495K Jan 1, 2020 Mar 31, 2020 6-K 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.